Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | USP7 | Q93009 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479380 | 0.94 | JAK2 (0.58) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL6486529 | 0.89 | GSK3B (0.63) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL6490350 | 0.87 | GSK3B (0.60) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL6477985 | 0.87 | GSK3B (0.56) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL6479743 | 0.87 | CDK2 (0.59) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL6478176 | 0.85 | GSK3B (0.61) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL6478798 | 0.82 | JAK2 (0.64) | PDPK1FGFR1GSK3BJAK2JAK1 | |
| SCHEMBL3359710 | 0.81 | FGFR1 (0.72) | PDPK1HSP90AB1FGFR1FGFR2GSK3B | |
| SCHEMBL10213932 | 0.81 | JAK2 (0.72) | PDPK1FGFR1FGFR2FGFR3JAK2 | |
| SCHEMBL17848181 | 0.77 | JAK2 (0.43) | PDPK1HSP90AB1FGFR1FGFR2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | PDPK1 4495/4885HSP90AB1 3650/4885FGFR1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.